Mitochondrial DNA Biomarker Discovery and Validation for the Detection, Prognosis and Treatment of Prostate Cancer
Abstract
The mitochondrial genome offers excellent potential as a DNA-based biomarker for cancer detection, as most tumors are composed of cells that each share thousands of identical somatic mtDNA point mutations, a phenomenon called homoplasmy. Here we propose the use of the sensitive mutation detection assays to test whether the frequency of circulating homoplasmic mtDNA tumor mutations in patients with prostate cancer would be a specific and sensitive marker of prostatic tumor therapeutic response, progression, and recurrence. Prostate cancer presents an ideal tumor model to test this new technology, as the frequency of prostate gland biopsy, homoplasmic mtDNA mutations, recurrence following radical prostatectomy are high.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2013
- Accession Number
- ADA595637
Entities
People
- Jason H. Bielas
Organizations
- Fred Hutchinson Cancer Center